MA54518B1 - 3béta- (benzyloxy)-17alpha-méthyl-pregn-5-en-20-one pour une utilisation dans le traitement de troubles cognitifs - Google Patents
3béta- (benzyloxy)-17alpha-méthyl-pregn-5-en-20-one pour une utilisation dans le traitement de troubles cognitifsInfo
- Publication number
- MA54518B1 MA54518B1 MA54518A MA54518A MA54518B1 MA 54518 B1 MA54518 B1 MA 54518B1 MA 54518 A MA54518 A MA 54518A MA 54518 A MA54518 A MA 54518A MA 54518 B1 MA54518 B1 MA 54518B1
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- cognitive disorders
- 17alpha
- 3beta
- pregn
- Prior art date
Links
- 208000010877 cognitive disease Diseases 0.000 title abstract 4
- IFFPDWXBMZYJMH-DFTYQABXSA-N 1-[(3S,8R,9S,10R,13S,14S,17S)-10,13,17-trimethyl-3-phenylmethoxy-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl]ethanone Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)(C)C(=O)C)CC1=CC=CC=C1 IFFPDWXBMZYJMH-DFTYQABXSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 150000003131 pregnenolone derivatives Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La présente invention concerne de manière générale un dérivé de prégnénolone spécifique destiné à être utilisé dans le traitement de troubles cognitifs. Plus précisément, l'invention concerne un composé de formule (I), destiné à être utilisé dans le traitement de troubles cognitifs. En effet, le composé de l'invention présente, in vivo, une action très puissante de correction des déficiences cognitives associées aux troubles cognitifs.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306716.4A EP3669876A1 (fr) | 2018-12-18 | 2018-12-18 | 3béta- (benzyloxy)-17alpha-méthyl-pregn-5-en-20-one pour une utilisation dans le traitement de troubles cognitifs |
| EP19831675.4A EP3897655B1 (fr) | 2018-12-18 | 2019-12-18 | 3béta- (benzyloxy)-17alpha-méthyl-pregn-5-en-20-one pour une utilisation dans le traitement de troubles cognitifs |
| PCT/EP2019/085927 WO2020127468A1 (fr) | 2018-12-18 | 2019-12-18 | 3β-(BENZYLOXY)-17α-METHYL-PREGN-5-EN-20-ONE DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT DE TROUBLES COGNITIFS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA54518A MA54518A (fr) | 2022-02-16 |
| MA54518B1 true MA54518B1 (fr) | 2024-11-29 |
Family
ID=65278139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA54518A MA54518B1 (fr) | 2018-12-18 | 2019-12-18 | 3béta- (benzyloxy)-17alpha-méthyl-pregn-5-en-20-one pour une utilisation dans le traitement de troubles cognitifs |
Country Status (25)
| Country | Link |
|---|---|
| EP (2) | EP3669876A1 (fr) |
| JP (1) | JP7515480B2 (fr) |
| KR (1) | KR102845328B1 (fr) |
| CN (1) | CN113260366B (fr) |
| AU (1) | AU2019409912B2 (fr) |
| BR (1) | BR112021011654A2 (fr) |
| CA (1) | CA3118210C (fr) |
| CL (1) | CL2021001458A1 (fr) |
| DK (1) | DK3897655T3 (fr) |
| ES (1) | ES2987823T3 (fr) |
| FI (1) | FI3897655T3 (fr) |
| HR (1) | HRP20241376T1 (fr) |
| HU (1) | HUE068626T2 (fr) |
| IL (1) | IL284032B2 (fr) |
| LT (1) | LT3897655T (fr) |
| MA (1) | MA54518B1 (fr) |
| MD (1) | MD3897655T2 (fr) |
| MX (1) | MX2021006904A (fr) |
| PL (1) | PL3897655T3 (fr) |
| PT (1) | PT3897655T (fr) |
| RS (1) | RS66013B1 (fr) |
| SI (1) | SI3897655T1 (fr) |
| SM (1) | SMT202400425T1 (fr) |
| WO (1) | WO2020127468A1 (fr) |
| ZA (1) | ZA202103284B (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024085245A1 (fr) | 2022-10-21 | 2024-04-25 | 国立大学法人高知大学 | Suppresseur de délire post-opératoire |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE453620T1 (de) * | 2003-05-01 | 2010-01-15 | Vernalis Res Ltd | Azetidincarboxamid-derivate zur verwendung zur behandlung von cb1-rezeptor-vermittelten krankheiten |
| EP2044029B1 (fr) * | 2006-07-14 | 2011-01-26 | Pfizer Products Inc. | Sel de tartrate de (7s)-7-[(5-fluoro-2-méthyl-benzyl)oxy]-2-[(2r)-2-méthylpipérazin-1-yl]-6,7-dihydro-5h-cyclopenta[b]pyridine |
| CN101790521A (zh) * | 2007-06-28 | 2010-07-28 | 英特维特国际股份有限公司 | 作为cb1拮抗剂的取代哌嗪 |
| PT2709631T (pt) * | 2011-05-20 | 2017-04-19 | Inserm - Inst Nat De La Santé Et De La Rech Médicale | Antagonistas de receptor de cb1 |
| DK2925770T3 (en) * | 2012-11-28 | 2017-04-10 | Univ Bordeaux | 3- (4'-SUBSTITUTED) -BENZYL-ETHER DERIVATIVES OF PREGNENOLONE |
| SMT202000164T1 (it) * | 2013-03-19 | 2020-05-08 | Univ Pompeu Fabra | Antagonisti del recettore cannabinoide cb1 per uso nel trattamento di malattie associate con anomalie dendritiche neuronali |
-
2018
- 2018-12-18 EP EP18306716.4A patent/EP3669876A1/fr not_active Withdrawn
-
2019
- 2019-12-18 MA MA54518A patent/MA54518B1/fr unknown
- 2019-12-18 MX MX2021006904A patent/MX2021006904A/es unknown
- 2019-12-18 IL IL284032A patent/IL284032B2/en unknown
- 2019-12-18 EP EP19831675.4A patent/EP3897655B1/fr active Active
- 2019-12-18 DK DK19831675.4T patent/DK3897655T3/da active
- 2019-12-18 FI FIEP19831675.4T patent/FI3897655T3/fi active
- 2019-12-18 JP JP2021534632A patent/JP7515480B2/ja active Active
- 2019-12-18 SI SI201930837T patent/SI3897655T1/sl unknown
- 2019-12-18 CN CN201980081303.1A patent/CN113260366B/zh active Active
- 2019-12-18 WO PCT/EP2019/085927 patent/WO2020127468A1/fr not_active Ceased
- 2019-12-18 LT LTEPPCT/EP2019/085927T patent/LT3897655T/lt unknown
- 2019-12-18 CA CA3118210A patent/CA3118210C/fr active Active
- 2019-12-18 KR KR1020217019491A patent/KR102845328B1/ko active Active
- 2019-12-18 ES ES19831675T patent/ES2987823T3/es active Active
- 2019-12-18 SM SM20240425T patent/SMT202400425T1/it unknown
- 2019-12-18 BR BR112021011654-0A patent/BR112021011654A2/pt unknown
- 2019-12-18 AU AU2019409912A patent/AU2019409912B2/en active Active
- 2019-12-18 HR HRP20241376TT patent/HRP20241376T1/hr unknown
- 2019-12-18 RS RS20241106A patent/RS66013B1/sr unknown
- 2019-12-18 HU HUE19831675A patent/HUE068626T2/hu unknown
- 2019-12-18 PL PL19831675.4T patent/PL3897655T3/pl unknown
- 2019-12-18 MD MDE20211041T patent/MD3897655T2/ro unknown
- 2019-12-18 PT PT198316754T patent/PT3897655T/pt unknown
-
2021
- 2021-05-14 ZA ZA2021/03284A patent/ZA202103284B/en unknown
- 2021-06-03 CL CL2021001458A patent/CL2021001458A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA64510B1 (fr) | Agonistes du récepteur glp-1 et leurs utilisations | |
| MA54229B1 (fr) | Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp | |
| ZA202409975B (en) | Methods of treating schizophrenia | |
| MA51204B1 (fr) | Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique | |
| MA39427A1 (fr) | Composés pyrrolidine modulateurs de gpr40 pour le traitement de maladies telles que le diabète | |
| MA37866B1 (fr) | Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur | |
| MA40254B1 (fr) | Polymorphes du selinexor | |
| MA31843B1 (fr) | Utilisation d'un bêta-bloquant pour la fabrication d'un médicament pour le traitement des hémangiomes | |
| MA43468A1 (fr) | Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2 | |
| TN2015000547A1 (fr) | Composes heteroaromatiques et leur utilisation comme ligands de dopamine d1 | |
| EA202191519A1 (ru) | Модуляторы trex1 | |
| WO2019007696A1 (fr) | Nouveaux composés et compositions pharmaceutiques de ceux-ci destinés au traitement de la fibrose | |
| MA40863A (fr) | Thiazoles en tant que modulateurs de roryt | |
| MA32506B1 (fr) | Nouveaux composes | |
| MA43052B1 (fr) | Inhibiteurs de la kallicréine plasmatique humaine | |
| EA202190272A1 (ru) | Дополнительно замещенные производные триазолохиноксалина | |
| MX2021007258A (es) | Composiciones de esparsentan amorfas. | |
| EA202091429A1 (ru) | Замещенные амиды i пирролидина | |
| EA202190271A1 (ru) | Замещенные триазолохиноксалиновые производные | |
| MA43913A (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique | |
| MA58018B1 (fr) | Carboxamides de thiophène substitués et leurs dérivés | |
| MA54518B1 (fr) | 3béta- (benzyloxy)-17alpha-méthyl-pregn-5-en-20-one pour une utilisation dans le traitement de troubles cognitifs | |
| MA43231B1 (fr) | Bloqueur des canaux sodiques | |
| MX2022005084A (es) | Formas sólidas de un modulador del receptor s1p a. | |
| MA56501A (fr) | Composés destinés au traitement de troubles neuromusculaires |